

ANTARES PHARMA, INC.  
Form 25  
June 26, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 25**

**NOTIFICATION OF REMOVAL FROM LISTING AND/OR**  
**REGISTRATION UNDER SECTION 12(b) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934.**

Commission File Number 001-32302

**ANTARES PHARMA, INC. NYSE AMEX**

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

**100 Princeton South, Suite 300, Ewing, NJ 08628; (609) 359-3020**

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

**Common Stock, par value \$0.01 per share**

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

.. 17 CFR 240.12d2-2(a)(1)

.. 17 CFR 240.12d2-2(a)(2)

.. 17 CFR 240.12d2-2(a)(3)

.. 17 CFR 240.12d2-2(a)(4)

Edgar Filing: ANTARES PHARMA, INC. - Form 25

.. Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

x Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.  
Pursuant to the requirements of the Securities Exchange Act of 1934, Antares Pharma, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

Date: June 25, 2012

By: /s/ Paul K. Wotton  
Name: Dr. Paul K. Wotton  
Title: President and Chief Executive Officer